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The Tasmanian devil facial tumor (DFT) disease has led to an 80% reduction in the wild
Tasmanian devil (Sarcophilus harrisii) population since 1996. The limited genetic diversity
of wild devils and the lack of MHC-I expression on DFT cells have been implicated
in the lack of immunity against the original DFT clonal cell line (DFT1). Recently, a
second transmissible tumor of independent origin (DFT2) was discovered. Surprisingly,
DFT2 cells do express MHC-I, but DFT2 cells appear to be on a trajectory for reduced
MHC-I expression in vivo. Thus, much of the ongoing vaccine-development efforts and
conservation plans have focused on MHC-I. A major limitation in conservation efforts
is the lack of species-specific tools to understand Tasmanian devil gene function and
immunology. To help fill this gap, we developed an all-in-one Tet-Off vector system to
regulate expression of IFN-γ in DFT cells (DFT1.Tet/IFN-γ). IFN-γ can have negative
effects on cell proliferation and viability; thus, doxycycline was used to suppress IFN-γ
production whilst DFT1.Tet/IFN-γ cells were expanded in cell culture. Induction of
IFN-γ following removal of doxycycline led to upregulation of MHC-I but also the
inhibitory checkpoint molecule PD-L1. Additionally, DFT1.Tet/IFN-γ cells were capable
of stimulating MHC-I upregulation on bystander wild type DFT cells in co-culture assays
in vitro. This system represents a major step forward in DFT disease immunotherapy
and vaccine development efforts, and ability to understand gene function in devils.
Importantly, the techniques are readily transferable for testing gene function in DFT2 cells
and other non-traditional species.
Keywords: transmissible tumor, DFTD, IFN-γ, MHC-I, Tet-Off system, inducible, PD-L1, apoptosis
INTRODUCTION
The Tasmanian devil facial tumor disease (DFTD) is caused by clonal transmissible cancers
(1, 2). The devil facial tumor 1 (DFT1) is primarily responsible for an 80% reduction in the
wild Tasmanian devil (Sarcophilus harrisii) population (3). The recently discovered devil facial
tumor 2 (DFT2) is a second transmissible tumor of independent origin that introduces additional
uncertainty about the long-term persistence of wild devils (2). Despite genetic mismatches between
tumor and host, most prominently in major histocompatibility complex (MHC) alleles, evidence
of anti-tumor immune responses are rare (4, 5). The limited evidence of host immune response
against DFT suggests effective immune evasion by the tumor cells. One such mechanism is the
epigenetic loss of MHC class I (MHC-I) molecules from the surface of DFT cells (6), which
facilitates escape from cytotoxic T cell recognition.
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Several preventative and therapeutic approaches have been
pursued to manage the spread of this debilitating disease, with
vaccination and immunotherapy having better success than
chemotherapy (7). Vaccines for DFTD have been formulated
using killed DFT cells, either frozen/thawed, sonicated, or
irradiated for safety reasons. The first immunization trial using
killed DFT cells with the adjuvantMontanide failed to trigger any
humoral or cytotoxic response (8) but the following trial, with the
addition of CpG, elicited antibody production and cytotoxicity in
five out of six immunized devils (9). The vaccine however, was
not fully protective as tumors developed upon challenge with live
DFT cells.
Treatment of DFT cells with recombinant devil IFN-γ induces
the expression of MHC-I heavy chain and genes essential
for MHC-I antigen processing and presentation including β2-
microglobulin (β2-m) (6, 10). A vaccine consisting of DFT cells
pre-treated with recombinant IFN-γ in cell culture and then
killed and mixed with adjuvants was used to prime the devil
immune system against DFT cells (11, 12). Serum antibodies
against MHC-I+ and MHC-I− DFT cells were detected but the
immunized devils developed tumors following infection with
live DFT cells (11). The devils were given immunotherapy
comprising of live IFN-γ treated MHC-I+ DFT cells and tumor
regression was induced in three of the six immunized devils
(11). Although prior exposure to DFT vaccines was necessary
to initiate tumor regression, this observation substantiates the
prospect of developing a live tumor cell vaccine for DFTD. A live-
attenuated DFTD vaccine could be more effective than killed-
cell vaccine preparations, as has been the case for conventional
live-attenuated vaccines that mimic a natural infection (13–17).
We have previously shown that IFN-γ also upregulates the
inhibitory checkpoint molecule programmed death ligand 1 (PD-
L1) on DFT1 and DFT2 cells (18). Binding of PD-L1 to PD-
1 blocks activation signals, particularly co-stimulatory signals
associated with antigen receptors on T cells and B cells (19–
21). This occurs via immunoreceptor tyrosine-based switch
motifs (ITSMs) and immunoreceptor tyrosine-based inhibitory
motifs (ITIMs) that recruit phosphatases that dephosphorylate
downstream signal transduction pathways (19). Upregulation of
PD-L1 on DFT cells appears to lag behind MHC-I upregulation
and peak expression levels of PD-L1 are at least an order of
magnitude lower than β2-m. This could provide a window of
opportunity for anti-DFT responses and immune checkpoint
immunotherapy that blocks the PD-1/PD-L1 pathway.
In developing a live-attenuated MHC-I+ DFT cell vaccine,
an alternative to treating DFT cells with exogenous IFN-γ is
to generate a DFT cell line that expresses IFN-γ. This would
be more cost-effective than using purified IFN-γ and has the
potential to be used as an immunotherapy to induce MHC-I
upregulation on bystander MHC-I− DFT cells in diseased devils.
One complication with using IFN-γ for MHC-I upregulation is
the anti-proliferative and pro-apoptotic properties of IFN-γ (22–
27) that will hinder the development of IFNγ-expressing DFT
Abbreviations: DFTD, devil facial tumor disease; DFT1, devil facial tumor 1;
DFT2, devil facial tumor 2; tet, tetracycline; dox, doxycycline; tTA, tet-controlled
transactivator; TCE, tet-responsive promoter; SB, Sleeping Beauty.
cells. Prolonged DFT cell culture with IFN-γ, even at doses as
low as 5 ng/ml, results in reduced proliferation and viability (28).
The large quantity of cells and secreted IFN-γ needed for a live-
attenuated vaccine to be effective in vivo would be difficult to
obtain due to the effects of IFN-γ in vitro. On the contrary, these
anti-proliferative and pro-apoptotic effects of IFN-γ would be
desirable aspects of a live-attenuated vaccine.
We hypothesized that the Tet-Off system, a tetracycline (tet)-
controlled regulatory system (29) could be employed to regulate
IFN-γ expression in DFT cells. The Tet-Off system regulates gene
expression by using a tetracycline (tet)-controlled transactivator
(tTA), which is active in the absence of tetracycline, to initiate
transcription of genes downstream to a tetracycline response
element andminimal CMV-promoter enhanced (TCE) promoter
(30). In the presence of tetracycline and its derivatives (e.g.,
doxycycline), tTA is bound by tetracycline and loses its DNA
binding ability, blocking transcription of genes reliant on the
TCE.
In this study, we demonstrate tight regulation of functional
IFN-γ production by DFT cells (referred to as DFT1.Tet/IFN-γ)
using doxycycline to switch IFN-γ on/off. MHC-I and inhibitory
checkpoint molecule PD-L1 were upregulated in response to
IFN-γ induction. Meanwhile, the anti-proliferative and pro-
apoptotic effects of IFN-γ were prevented by inhibiting IFN-
γ expression using doxycycline. Importantly, we also observed
an in vitro paracrine signaling bystander effect that upregulated
MHC-I on wild type DFT cells co-cultured with DFT1.Tet/IFN-
γ cells. This system can be applied to other genes to allow
understanding of gene function in Tasmanian devils and
opens pathways to develop live-attenuated vaccines and/or
immunotherapies for DFTD.
MATERIALS AND METHODS
Plasmid Construction
An expression vector for Tet-Off inducible devil IFN-γ (referred
to as pAF107) was constructed by fusing multiple fragments
using PCR and cloning methods (Figure 1A). The vector
backbone for pAF107 was generated from Sleeping Beauty
(SB) transposon plasmid pSBtet-RH (Addgene, Cambridge, MA,
USA), linearized by PCR. pSBtet-RH was a gift from Eric Kowarz
(30). The inserts for pAF107 consisted of four fragments that
were prepared as follows. Fragment 1 is a cassette containing red
fluorescent protein mCherry, followed by an internal ribosome
entry site (IRES), and devil IFN-γ cDNA (mCherry-IRES-IFNγ).
This cassette was obtained from plasmid pAF67, which was
constructed by cloning devil IFN-γ cDNA [PCR-amplified from
a pre-existing plasmid, pAF23 (18)] into the multiple cloning site
(MCS) of PCR-linearized pTRE-Dual2 (Clontech Laboratories,
Mountain View, CA, USA). Fragment 2 (SV40pA-RPBSA) was
obtained from pSBtet-RH, and fragment 3 (tTA) was obtained
from pTet-DualOFF (Clontech). Fragment 4 (P2A-devil 41BBL)
was obtained from a pre-existing plasmid encoding devil 4-
1BBL, pAF56.1. All fragments were obtained by PCR with
overlapping ends using KAPA Hotstart HiFi Master Mix (Kapa
Biosystems,Wilmington,MA,USA) (see Supplementary Table 1
for primers and PCR cycling conditions). The fragments were
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FIGURE 1 | Vector and study design of Tet-inducible IFN-γ-expressing DFT1 cells (DFT1.Tet/IFN-γ). (A) Expression vector for tetracycline (tet)-controlled inducible
IFN-γ expression in DFT1 cells. ITR, inverted terminal repeats; TCE, tet-responsive promoter; IRES, internal ribosomal entry site; tTA, tet-controlled transactivator.
(B) Timeline for dox+/– treatments of DFT1.Tet/IFN-γ used in subsequent experiments. DFT1.Tet/IFN-γ cultured in 100 ng/ml doxycycline (Dox) was split into four
groups with doxycycline removed or doxycycline continually replenished for 1, 2, 5, or 10 days. Cells were analyzed for: (i) surface β2-m and PD-L1 upregulation; (ii)
ability to stimulate MHC-I upregulation on wild type DFT1 cells (DFT1.WT) using the supernatant or by co-culture; and (iii) cell proliferation and viability in response to
doxycycline removal.
fused together by overlap extension PCR prior to cloning into
pAF107 vector backbone using NEBuilder R© HiFi DNAAssembly
Cloning Kit (NEB). All assembled plasmids were transformed
into NEB R© 5-alpha competent Escherichia coli (NEB) following
manufacturer’s instructions. Plasmid integrity was confirmed
by Sanger sequencing using BigDye R© Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems (ABI), Foster City, CA,
USA) and analysis on 3500xL Genetic Analyzer (ABI).
Cell Culture
The devil facial tumor 1 (DFT1) cell line C5065 (strain 3),
provided by A-M Pearse and K. Swift of the Department of
Primary Industries, Parks, Water and Environment (DPIPWE)
(Hobart, Australia) was used for all experiments. Cells were
cultured in complete RPMI medium, RPMI 1640 medium with
L-glutamine (Gibco, Waltham, MA, USA), supplemented with
10% heat inactivated fetal bovine serum (Bovogen Biologicals,
Melbourne, Australia), 1% Antibiotic-Antimycotic (Gibco),
10mM HEPES (Gibco), and 0.1mM 2-mercaptoethanol (Sigma-
Aldrich, St. Louis, MO, USA) at 35◦C with 5% CO2. Tet-Off
inducible IFNγ-expressing DFT cells (DFT1.Tet/IFN-γ) were
cultured in complete RPMI medium with 100 ng/ml doxycycline
(Clontech) unless indicated otherwise.
Transfection
C5065 cells were seeded onto a 6-well plate at a confluency
between 40 and 80% and were incubated overnight. The cells
were co-transfected with pAF107 and pCMV(CAT)T7-SB100
(Addgene) at a ratio of 9:1 (in µg), respectively, using a total
of 1–2 µg plasmid DNA. pCMV(CAT)T7-SB100 was a gift
from Zsuzsanna Izsvak (31) and is used to facilitate integration
of SB transposon vectors into the genome. Plasmid DNA was
diluted in serum-free RPMI and incubated for 2–5min at room
temperature. Polyethyleminine (PEI) (1 mg/ml, linear, 25 kDa;
Polysciences, Warrington, PA, USA) was added to the diluted
DNA at a 3:1 ratio and was mixed briefly by vortexing. The
solution was incubated for 15–30min at room temperature
before adding it to the cells. The cells were incubated with the
solution for 4 h, after which it was replaced with complete RPMI
medium.
Gene Induction and Suppression
For gene suppression, doxycycline (100 ng/ml) was added to
the culture medium and replenished every 2 days. For gene
induction, the medium was decanted, and the cells were rinsed
once with PBS (Oxoid, Hampshire, UK) while remaining adhered
to the surface. The cells were then harvested in PBS and pelleted
at 200 × g for 5min at 20◦C. The cells were resuspended
and cultured in complete RPMI medium in the absence of
doxycycline.
Flow Cytometric Cell Sorting
Doxycycline was removed from the culture medium at least
2 days prior to cell-sorting to turn on expression of reporter
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mCherry, which is co-expressed with IFN-γ under the control
of inducible TCE promoter. Cells were harvested at 200 × g for
5min at 20◦C and resuspended in complete RPMI medium to
generate a single-cell suspension. mCherry+ cells were selected
and enriched by bulk-sorting using cell sorter Moflo Astrios
EQ (Beckman Coulter). After sorting, the cells were cultured
with doxycycline (100 ng/ml) and expanded for a month before
undergoing a second round of enrichment by bulk-sorting.
Detection of IFN-γ, β2-m, and PD-L1 mRNA
by RT-PCR
Total RNA was extracted from cells using Nucleospin R© RNA
plus (Macherey Nagel, Bethlehem, PA, USA). RNA integrity
was validated by running on a 1% agarose gel at 100V for
30min before proceeding to cDNA synthesis. One µg of RNA
was reverse-transcribed to cDNA using GoScriptTM Reverse
Transcription System (Promega, Madison, WI, USA). A no-
reverse transcriptase (no-RT) control was included for each
RNA sample to verify absence of genomic DNA contamination.
IFN-γ, β2-m, and PD-L1 cDNA were amplified by PCR,
generating products of 310, 301, and 280 bp, respectively
(see Supplementary Table 2 for primers and PCR cycling
conditions). The housekeeping gene GAPDH was used as a
reference gene. Primers for IFN-γ, PD-L1, and GAPDH were
designed using SnapGene R© against mRNA sequences from the
Tasmanian devil Reference Genome Devil_ref v7.0 assembly
GCF_000189315.1. Primers for β2-m were designed as previously
described (6). PCR reactions were carried out using Q5 R© Hot
Start High-Fidelity 2X Master Mix (NEB), and the products were
run on a 1% agarose gel at 100V for 30min.
Analysis of MHC-I and PD-L1 Surface
Expression by Flow Cytometry
Cells (1 × 105 per well) were harvested in a round-bottom 96-
well plate at 500 × g for 3min at 4◦C. The cells were blocked
with 1% normal goat serum (Thermo Fisher Scientific, Waltham,
MA, USA) in FACS buffer (PBS with 0.5% BSA, 0.05% NaN3)
for 10min on ice, followed by incubation with 0.4 µl/sample
of anti-devil β2-m mouse antibody (gift from Hannah Siddle)
(10) for 15min on ice. After incubation, the cells were washed
by adding 150 µl FACS buffer and centrifuging at 500 × g for
3min at 4◦C. 0.4 µg/sample of secondary antibody goat anti-
mouse IgG-Alexa Fluor 488 (Thermo Fisher Scientific) was added
to the cells and incubated for 15min on ice. The cells were washed
twice with FACS buffer to remove excess secondary antibody, and
then incubated with mouse anti-devil PD-L1 clone 1F8 antibody
(18) labeled with DyLight 650 using DyLight
TM
650 Microscale
Antibody Labeling Kit (Thermo Fisher Scientific) for 15min
on ice. The cells had a final rinse with FACS buffer and were
resuspended in 200 µl DAPI (200 ng/ml) (Sigma-Aldrich). The
cells were analyzed on Moflo Astrios EQ for β2-m and PD-L1
surface expression.
Stimulation of MHC-I on C5065 Cells Using
Supernatant From DFT1.Tet/IFN-γ
DFT1.Tet/IFN-γ (2 × 106 cells per flask) were seeded in 25 cm2
cell culture flasks. After culturing for 24 h, the supernatant was
collected, centrifuged at 3200 × g for 10min at 4◦C, and passed
through a 0.22µm filter membrane. One ml of supernatant was
added to wild type C5065 cells (2 × 105 cells per well) seeded on
12-well plates the day before. C5065 cells were stimulated with
the supernatant for 48 h and MHC-I upregulation was quantified
by flow cytometry based on β2-m expression (according to
the method described above excluding anti-PD-L1 antibody
staining). The cells were analyzed on BD FACSCantoTM II (BD
Biosciences, Franklin Lakes, NJ, USA).
Stimulation of MHC-I on C5065 Cells
Through Co-culture With DFT1.Tet/IFN-γ
DFT1.Tet/IFN-γ was co-cultured in triplicate at a ratio of 1:1
with C5065 cells labeled with CellTrace Far Red (Thermo Fisher
Scientific) in 12-well plates (total of 1 × 105 cells per well)
for 4 days. The cells were analyzed for MHC-I upregulation by
flow cytometry (according to the method described above) using
Moflo Astrios EQ.
Cell Proliferation Assay
Cell proliferation was analyzed by water-soluble tetrazolium-8
(WST-8) proliferation assay using Cell Counting Kit-8 (CCK-8)
(Sigma Aldrich). Cells (1 × 104 per well in 100 µl suspension)
were inoculated in triplicate in 96-well plates. Ten microliter
CCK-8 solution was added to each well and the plate was
incubated for 4 h at 35◦C. Absorbance at 450 nm was measured
on the day of inoculation to determine the baseline absorbance
of cells for each sample, and after 2 days of incubation to assess
change in absorbance using plate reader Spark R© 20M (Tecan,
Männedorf, Switzerland).
Cell Death Assay
Cells (2 × 105 per well) were seeded in 12-well plates in
triplicate. The percentage of cell death over 2 days was quantified
by staining cells with DAPI (200 ng/ml) and analysis by flow
cytometry using Moflo Astrios EQ.
RESULTS
Regulation of IFN-γ by Doxycycline
Before developing a Tet-Off inducible expression system for
IFN-γ, we conducted a preliminary experiment investigating
the utility of this system in DFT cells. We transfected C5065
cells (a DFT1 cell line) initially with the pTet-DualOff vector
(Supplementary Figure 1A) for expression of the tet-controlled
transactivator (tTA) and used flow cytometry to sort the
cells based on ZsGreen expression to generate a stable cell
line. We then transfected this cell line with the pTRE-
Dual2 vector (Supplementary Figure 1A), which contains the
tet-responsive promoter (TRE) and reporter gene mCherry.
We sorted for double positive cells expressing both ZsGreen
and mCherry, and then analyzed the expression of the
mCherry reporter protein in response to culture with and
without doxycycline. Our preliminary experiment demonstrated
tight, reversible gene regulation with this dual-color system
(Supplementary Figure 1B).
We then constructed an all-in-one SB Tet-Off vector (pAF107)
that contained the tet-controlled transactivator (tTA) and the
Frontiers in Immunology | www.frontiersin.org 4 January 2019 | Volume 9 | Article 3117
Ong et al. Inducible IFN-γ for MHC-I Upregulation
FIGURE 2 | Gene expression following doxycycline removal and the downstream effects of IFN-γ. (A) Flow cytometric analysis of mCherry expression in
DFT1.Tet/IFN-γ with and without doxycycline. DFT1.WT cells treated with and without 5 ng/ml IFN-γ for 24 h (B,C) or 72 h (D) were used as positive and negative
controls for β2-m and PD-L1 upregulation, respectively. (B) mRNA expression of IFN-γ, β2-m and PD-L1 analyzed by RT-PCR. Results are shown for DFT1.Tet/IFN-γ
cells cultured with and without doxycycline for 5 days, and GAPDH was used as a reference gene. NTC, no template control. Marker shows 250 bp-size band.
(C) β2-m upregulation on DFT1.Tet/IFN-γ following doxycycline removal. Cells were stained with mouse anti-devil β2-m antibody followed by goat anti-mouse IgG
conjugated to AlexaFluor 488 and were analyzed by flow cytometry. (D) PD-L1 upregulation on DFT1.Tet/IFN-γ following doxycycline removal. Cells were stained with
mouse anti-devil PD-L1 antibody conjugated to DyLight 650 and were analyzed by flow cytometry. For both flow cytometric analyses, antibody staining of cells was
performed in triplicate and dead cells were excluded by DAPI staining. The results shown are representative of n = 3 replicates/treatment.
tet-responsive promoter (TCE) for inducible expression of IFN-
γ (Figure 1A) in DFT1 C5065 cells (DFT1.Tet/IFN-γ). The
single vector approach simplifies cell line development and
ensures a 1:1 ratio of transactivator and response element
integration into the host cell genome. To analyze the regulation
of IFN-γ by doxycycline, we split DFT1.Tet/IFN-γ into four
groups of increasing periods of induction (1, 2, 5, and 10 days
without doxycycline) (Figure 1B). For each group of cells with
doxycycline removed, there was a replicate with doxycycline
continually added. Expression of the reporter protein mCherry
was quantified by flow cytometry and was used as a proxy
for IFN-γ induction (Figure 2A). mCherry expression was
consistently absent in all groups cultured with doxycycline, but
mCherry expression was detectable by day 2 post-doxycycline
removal and increased over time. These results suggest that
the all-in-one system tightly regulates expression of genes
downstream to the tetracycline-responsive promoter.
MHC-I and PD-L1 Upregulation Following
IFN-γ Induction
Two of the downstream effects of IFN-γ include upregulation of
MHC-I and the inhibitory checkpoint molecule PD-L1 (6, 18).
We used RT-PCR to initially examine mRNA levels of IFN-
γ, MHC-I subunit β2-m, and PD-L1 in cells with and without
doxycycline for 5 days to qualitatively determine expression
levels before embarking on protein-based immunology. β2-m
and PD-L1 were upregulated in cells with doxycycline removed
(Figure 2B). This suggests that DFT1.Tet/IFN-γ cells produce
functional IFN-γ in the absence of doxycycline. Conversely, IFN-
γ, β2-m, and PD-L1 mRNA expression in DFT1.Tet/IFN-γ cells
cultured with doxycycline was on par with expression in wild type
cells.
Cell surfaceMHC-I and PD-L1 protein upregulation were also
analyzed by flow cytometry. Surface expression of MHC-I was
determined using a monoclonal antibody to β2-m (10). Upon
doxycycline removal, β2-m upregulation was observed by the
second day and was strongly upregulated in all cells at 5 and
10 days without doxycycline (Figure 2C). This was consistent
with the temporal induction of IFN-γ observed in Figure 2A, as
represented by reporter mCherry. PD-L1 upregulation following
doxycycline removal also mirrored results previously obtained
using exogenous IFN-γ treatment (18) (Figure 2D). As expected,
β2-m and PD-L1 expression were absent on the surface of cells
cultured with doxycycline.
Bystander Effects of DFT1.Tet/IFN-γ
As cytokines act on cells in both an autocrine and paracrine
fashion, we wanted to determine if IFN-γ secreted by
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FIGURE 3 | Bystander effects of DFT1.Tet/IFN-γ. (A) Flow cytometric analysis
of β2-m upregulation on wild type DFT1 cells (DFT1.WT) after 48 h of
stimulation with supernatant from DFT1.Tet/IFN-γ cultured with or without
doxycycline for 1, 2, 5, and 10 days. Controls include DFT1.WT treated with
complete media, 5 ng/ml IFN-γ or supernatant from DFT1.WT cells. (B) β2-m
expression on DFT1.WT cells following 4 days of co-culture of DFT1.WT and
DFT1.Tet/IFN-γ. DFT1.Tet/IFN-γ were cultured either with doxycycline (+Dox)
or without doxycycline (–Dox) for 1, 2, 5, and 10 days prior to initiating the
co-culture assay. DFT1.WT cells were pre-labeled with CellTrace Far Red
(CTFR). The cells were stained for β2-m and analyzed by flow cytometry.
DFT1.WT cells treated with and without 5 ng/ml IFN-γ for 24 h were used as
positive and negative controls, respectively. Each treatment and co-culture
were carried out in triplicate. The results shown are representative of n = 3
replicates/treatment.
DFT1.Tet/IFN-γ could upregulate MHC-I on wild type DFT1
cells (DFT1.WT) through paracrine signaling. We collected
supernatant from each group of DFT1.Tet/IFN-γ (i.e., with and
without doxycycline for 1, 2, 5, and 10 days) and used the
supernatant to stimulate DFT1.WT cells (Figure 1B). Consistent
with the results above, β2-m upregulation was only observed in
DFT1.WT cells treated with supernatant from DFT1.Tet/IFN-
γ with doxycycline removed for 2, 5, and 10 days (Figure 3A).
Due to a reduced cell number of DFT1.Tet/IFN-γ cells with
doxycycline removed for 10 days (5 ×105 cells as opposed to 2
× 106 cells in all other groups), β2-m upregulation in DFT1.WT
cells treated with supernatant from this group appeared less than
expected. The lower number of cells for this group was a result of
reduced proliferation after the last passage.
The bystander effects of IFN-γ were also investigated by co-
culture of DFT1.Tet/IFN-γ with DFT1.WT cells. DFT1.Tet/IFN-
γ with doxycycline removed for 1, 2, 5, and 10 days were co-
cultured with DFT1.WT pre-labeled with CellTrace Far Red
(CTFR), respectively, at a ratio of 1:1 for 4 days (Figure 1B).
Flow cytometric analysis of β2-m on CTFR
+ DFT1.WT revealed
the ability of DFT1.Tet/IFN-γ cultured without doxycycline to
stimulate β2-m upregulation on neighboring DFT1.WT cells
(Figure 3B).
Inhibition of Anti-proliferative and
Pro-apoptotic Effects of IFN-γ Using
Doxycycline
To explore the effects of IFN-γ on cell proliferation and
viability using the Tet-Off system, we examined differences in
proliferation and cell death of DFT1.Tet/IFN-γ cells with and
without doxycycline relative to DFT1.WT cells. Proliferation and
cell death over 2 days (t = −2 to t = 0, Figure 1B) were assessed
by WST-8 proliferation assay, and quantification of dead cells by
DAPI staining and analysis by flow cytometry. In the absence
of doxycycline, proliferation, and viability of DFT1.Tet/IFN-γ
cells were reduced at 10 days, but not in cells with doxycycline
removed for 1, 2, and 5 days (Figures 4A,B). DFT1.Tet/IFN-γ
cells cultured with doxycycline were demonstrated to proliferate
and have viabilities similar to DFT1.WT cells (Figures 4A,B).
DISCUSSION
Upregulation of MHC-I on DFT cells by recombinant IFN-γ
prior to vaccination and immunotherapy has been associated
with anti-DFT immune responses (12). Importantly, tumor
regressions have been induced only when using live-MHC-I+
DFT cell immunotherapy in infected devils that were vaccinated
prior to infection with DFT cells (11). Live-cell immunotherapy
has the obvious risk of seeding new tumors into infected devils,
and a live-cell prophylactic vaccine introduces the risk of seeding
tumors into previously tumor-free devils. The tight regulation of
IFN-γ production by the Tet-Off system allowed us to develop
a cell line that can be easily cultured in vitro but rapidly
decreases in viability and increases in immunogenicity (i.e.,
MHC-I upregulation) upon removal of doxycycline. Increased
immunogenicity and reduced capacity for proliferation are key
attributes of successful live-attenuated vaccines (32–34).
The previously used immunotherapy method of treating wild
type DFT cells in vitro with IFN-γ prior to injecting the live
MHC-I+ DFT cells into infected devils relies on igniting a
sustained immune response for ongoing IFN-γ production. As
upregulation of MHC-I is transient on DFT cells following IFN-
γ exposure (28), it is possible that the pre-treated DFT cells could
survive long enough in vivo to downregulate MHC-I expression
and escape anti-tumor immunity. Although not tested in vivo
yet due to the limitations of working with endangered species,
injecting live DFT1.Tet/IFN-γ directly into facial tumors could
provide elevated levels of IFN-γ production in vivo. This may
enhance T cell-mediated anti-tumor responses, and the anti-
proliferative and pro-apoptotic effects of IFN-γ on DFT cells
should also increase the safety of using live tumor cells for
immunotherapy. Importantly, the bystander effect of MHC-I
upregulation on nearby wild type DFT cells demonstrated here
could initiate a more reliable and sustained anti-tumor response.
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FIGURE 4 | Anti-proliferative and pro-apoptotic effects of IFN-γ are ameliorated in DFT1.Tet/IFN-γ cultured with doxycycline. Cell proliferation and viability of
DFT1.Tet/IFN-γ was compared against DFT1.WT cells cultured with or without 50 ng/ml IFN-γ for 10 days. (A) Differences in proliferation of DFT1.Tet/IFN-γ in the
presence and absence of doxycycline for 1, 2, 5, and 10 days, assessed by WST-8 proliferation assay. The WST-8 assay uses absorbance at 450 nm as a proxy for
the number of viable cells. Baseline absorbance was measured 2 days prior (t = −2) and change in absorbance was measured after 2 days (t = 0). Graph shows the
average value of triplicates and a standard deviation error bar. (B) Cell viability of DFT1.Tet/IFN-γ in the presence and absence of doxycycline for 1, 2, 5, and 10 days.
Cell death over 2 days (from t = −2 to t = 0) was quantitated by staining dead cells with DAPI and analysis by flow cytometry. The results shown are representative of
n = 3 replicates/treatment. The percentages in the upper right and left quadrants were added to yield the total percentage of dead cells while the same was done for
the lower quadrants to give the total percentage of viable cells.
The bystander effect of DFT1.Tet/IFN-γ shown here is also
comparable to the effects of autocrine IFN-γ acting on the
cells, which reinforces the use of these cells for immunotherapy.
The extent of MHC-I upregulation on wild type DFT cells
stimulated with supernatant from DFT1.Tet/IFN-γ without
doxycycline (Figure 3A) were similar to their respective groups
of DFT1.Tet/IFN-γ cells (Figure 2C) except for day 10 without
doxycycline. The reduced upregulation on DFT cells treated
with supernatant from this group was anticipated due to the
lower number of DFT1.Tet/IFN-γ cells present compared to the
other groups. This is attributed to the anti-proliferative and pro-
apoptotic effects of IFN-γ with longer periods of induction. At
10 days without doxycycline, DFT1.Tet/IFN-γ had a substantially
lower metabolic activity (Figure 4A), which validates the reduced
proliferation observed after the last passage. Additionally, the
IFNγ-mediated increased cell death shown in Figure 4B is
another contributing factor to reduced cell expansion in culture.
The upregulation of PD-L1 following IFN-γ expression could
pose a challenge in eliciting an effective vaccine-induced immune
response. PD-L1 expression in the tumor microenvironment has
been shown to inhibit T cell responses via several mechanisms
such as: (i) promoting T cell apoptosis (35); (ii) inhibiting T
cell activation in terms of proliferation and cytokine production
(36, 37); and (iii) suppressing cytotoxic T cell killing (38). We
have previously shown that PD-L1 is typically absent or expressed
at very low levels on DFT cells but is upregulated by IFN-γ
(18). This problem could be eliminated by knocking out the
PD-L1 gene in live-attenuated DFT cells, but the bystander
effect in the tumor microenvironment could lead to PD-L1-
mediated inhibition of anti-tumor immunity. Alternatively, given
the success of PD-1/PD-L1 blocking antibodies in human cancer,
incorporating existing devil PD-1/PD-L1 blocking antibodies in
immunotherapies and vaccines could be an effective means to
amplify anti-DFT responses. Another potential approach that can
be explored with the system developed here is to modify the
tumor cells to produce the blocking antibodies (39). This would
actually be more cost-effective than using purified antibodies.
The ability to suppress the anti-proliferative and pro-
apoptotic effects of IFN-γ suggests that other genes that can
kill tumor cells could be suppressed during cell culture but
are activated during vaccination or immunotherapy. The ability
to manipulate gene expression exogenously opens new avenues
for DFTD vaccine research, such as incorporating “suicide
genes” into DFT cells for attenuation of a live-attenuated tumor
cell vaccine. Pro-apoptotic molecules such as BAX could be
suppressed in culture to allow expansion of the cells, but then
activated in vivo to ensure that new tumors are not seeded into
healthy devils.
The SB transposon system provides stable integration of DNA
cargo into the target cell genome (30). The stability and safety
of the SB system have been demonstrated in chimeric antigen
receptor T cells (CAR-T) in human clinical trials for advanced
non-Hodgkin lymphoma and acute lymphoblastic leukemia (40).
The simple all-in-one SB vector developed here contains both
elements of the Tet-Off system, the tetracycline (tet)-controlled
transactivator (tTA), and the tet-responsive promoter (TCE).
Consequently, the process of generating stable transgenic cell
lines by eliminating the need for dual transfection and multiple
rounds of selection by cell sorting is streamlined. The ability
to precisely regulate gene expression and assess downstream
biological effects on tumor cells and interactions with immune
cells should facilitate rapid advances in the understanding of the
devil facial tumor biology and the devil immune system.
In summary, here we demonstrate the development of an
effective inducible gene expression system for DFT cells using
the Tet-Off system. Through this system, we were able to
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generate IFNγ-expressing DFT cells for MHC-I upregulation
without compromising cell proliferation and viability in culture
by controlling IFN-γ expression at a transcriptional level. The
ability to precisely manipulate gene expression using the Tet-
Off system has also allowed us to establish a method of studying
gene function in Tasmanian devils and is the first step toward a
live-attenuated DFT vaccine.
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